- Pain response (defined as at least a 30% decrease from baseline in average BPI-SF pain intensity scores) was observed in 46% of patients with cabazitaxel versus 19% with abiraterone or enzalutamide (P<0.0001).
- Median time to pain progression was not estimable with cabazitaxel and was 8.5 months with abiraterone or enzalutamide (HR=0.55, 95%CI 0.32-0.97; log-rank P=0.035).
- Median time to symptomatic skeletal events (defined as either the use of external beam radiotherapy to relieve bone pain, occurrence of new symptomatic pathological fractures, occurrence of spinal compression, or tumour-related orthopaedic surgical intervention) was not estimable with cabazitaxel, and was 16.7 months with abiraterone or enzalutamide (HR=0.59, 95%CI 0.35–1.01; log-rank P=0.050).
- Median time to Functional Assessment of Cancer Therapy-Prostate (FACT-P) score deterioration was 14.8 months with cabazitaxel versus 8.9 months with abiraterone or enzalutamide (HR=0.72, 95%CI 0.44‒1.20; log-rank P=0.21).
- There was a significant treatment effect seen in changes from baseline in the EuroQoL-5 dimensions, with the 5-level scale (EQ-5D-5L) utility index score favouring cabazitaxel over abiraterone or enzalutamide (P=0.030), but no difference was found for the EQ-5D-5L visual analogue scale (P=0.060).
Metastatic prostate cancer: cabazitaxel shows quality of life benefits over both abiraterone and enzalutamide
